Related Experiment Video
Updated: Aug 1, 2026
11:34
High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
Published on: May 5, 2014
14.5K
Toll-like receptor 2 antagonists identified through virtual screening and experimental validation
Prasannavenkatesh Durai1, Hyeon-Jun Shin1, Asma Achek1
1Department of Molecular Science and Technology, Ajou University, Suwon, Korea.
The FEBS Journal
|June 2, 2017
Summary
Two novel nonpeptide Toll-like receptor 2 (TLR2) antagonists, C11 and C13, were identified via virtual screening. These compounds effectively inhibit TLR2 activation, offering potential for new anti-inflammatory drug development.
Area of Science:
- Immunology
- Pharmacology
- Drug Discovery
Background:
- Toll-like receptor 2 (TLR2) antagonists are crucial for managing inflammatory diseases.
- Excessive TLR2 activation is implicated in various pathological conditions.
Purpose of the Study:
- To identify novel nonpeptide TLR2 antagonists.
- To validate the efficacy and specificity of newly discovered compounds.
Main Methods:
- Pharmacophore-based virtual screening to identify potential candidates.
- In vitro assays using human embryonic kidney and RAW 264.7 cells to assess IL-8 and TNF-α inhibition.
- Surface plasmon resonance (SPR) for direct binding analysis.
- Cell viability assays (MTT) to confirm compound safety.
Main Results:
- Two novel nonpeptide TLR2 antagonists, C11 and C13, were successfully identified.
- C11 and C13 demonstrated potent inhibition of IL-8, comparable to a known TLR2 inhibitor.
- Compounds showed TLR2 specificity, not affecting TLR3 or TLR4 pathways.
- Direct binding to the TLR2 ectodomain was confirmed via SPR.
- No significant cytotoxicity was observed in cell viability assays.
Conclusions:
- C11 and C13 are effective TLR2 antagonists with demonstrated specificity and safety.
- These compounds offer valuable insights into TLR2 antagonist structure-activity relationships.
- The findings pave the way for developing novel TLR2-targeted therapeutics for inflammatory diseases.
More Related Videos
Related Concept Videos
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...